Experience with a novel Nd:YAG laser


The Nd:YAG laser plays a key part in ophthalmology. However, it is important to select a device that enables the best treatment results using lower energy and fewer shots

TheNd:YAG laser plays a key part in ophthalmology. However, it is important to select a device that enables the best treatment results using lower energy and fewer shots

Modern cataract surgery can provide good visual outcomes for most patients, thanks to developments in surgical technique, instrumentation and intraocular lens (IOL) technology. Unfortunately, despite advances in lens design and material, we cannot always prevent the main complication associated with cataract surgery: posterior capsule opacification (PCO). The use of neodymium-doped yttrium aluminum garnet (Nd:YAG) laser capsulotomy allows for a safe and non-invasive method of managing PCO.

Use of the Nd:YAG laser is not limited to capsulotomies. It is also frequently used to undertake peripheral iridotomies in patients with acute and narrow angle-closure glaucoma. Nd:YAG lasers are also used by some surgeons to vaporise symptomatic vitreous floaters. Not surprisingly, the Nd:YAG laser has become an essential feature of most ophthalmology clinics.

Laser choice

The Nd:YAG laser has come a long way since it was first demonstrated in the 1960s, and there are now several Nd:YAG devices available. Previously, I used the YC-1800 from Nidek. However, our department recently switched to the OptoYag M (Optotek Medical, Ljubljana, Slovenia).

The main reason we chose this particular laser was because it enables the best treatment results using lower energy and fewer shots.1 Although Nd:YAG capsulotomy is known to have a good safety profile, there is a small risk of complications, including retinal tears and detachment, cystoid macular oedema, IOL damage, iritis, and transient or persistent elevation of intraocular pressure. Findings from numerous studies suggest that side-effects are more pronounced when a high single-pulse energy is used. Consequently, many surgeons perform Nd:YAG capsulotomies at the lowest possible energy level.2-7

One of the most helpful features of the OptoYag M is its ability to deliver 30 different energy levels between 0.5 mJ and 10 mJ. This allows me to precisely adjust the energy in order to match the specific needs of the particular treatment and the patient’s eye response. The system also features a repetition rate of 3 Hz, which affords faster treatment. This feature is not only beneficial for practice productivity, it also increases patients’ comfort levels. Another feature that supports patient ease is the LED slit lamp incorporated into the device. Unlike many other slit lamps, it emits minimal heat, which is important for patient comfort, particularly in those with dry eye.


I have also found that this device allows accurate, repeatable and consistent delivery of energy. Some YAG lasers can be temperamental, particularly in terms of accuracy, but the OptoYag M has proven to be reliable thanks to the incorporation of pulse-to-pulse stability (PPS) technology which delivers a stable energy output that exceeds current industry standards (Figure 1). Enhanced accuracy and stability of laser energy not only helps to improve safety, it also increases treatment efficacy. Because the OptoYag M has a red diode aiming beam with continuous power adjustment that allows precise focusing of the YAG laser, I find I don’t need to use a contact lens in most cases, further simplifying the procedure.

Another advantage is that the OptoYag M has a convenient portable design. Because the electronics box is positioned under the table, the system can be moved freely to another worktop and is therefore instantly ready to use.

Clinical experience

We’ve used the OptoYag M in hundreds of patients for both capsulotomies and iridotomies. I find that I can achieve a successful capsulotomy at an energy level between 1.0 mJ and 1.6 mJ, typically using only 10 to 12 shots. For an iridotomy, I tend to use an energy level of 2.5 mJ at two pulses. A study undertaken by Hawlina and Drnovšek-Olup at the University Medical Centre Ljubljana, Slovenia, showed that Nd:YAG laser capsulotomies could be successfully undertaken using the OptoYag M at an energy level of 1.6 mJ. In this study, which included 53 eyes of 44 patients (mean age, 76.49 years; [range, 59 to 89 years]), all procedures were performed with an energy level of 1.6 mJ and an average total energy of 104.72 mJ (range, 27.2 mJ to 320 mJ). The average number of pulses used was 65.5, ranging from 17 to 200. All treatments were successful.1

Although I haven’t conducted a formal study of the OptoYag M laser, my capsulotomy patients generally report immediate improvements in PCO symptoms. Moreover, I haven’t had to repeat the procedure in any patient and there have been no serious complications.

Masoud Teimory, MB ChB, FRCOphth, is a consultant ophthalmic surgeon at Western Sussex Hospitals NHS Trust, UK. He states that he has no financial interests in Optotek Medical. Masoud.Teimory@wsht.nhs.uk



1. Hawlina G, Drnovšek-Olup B. Nd:YAG laser capsulotomy for treating posterior capsule opacification. J Laser Health Acad 2013; 1: S34-S35.

2. Aron-Rosa DS, Aron JJ, Cohn HC. Use of a pulsed picosecond Nd:YAG laser in 6,664 cases. J Am Intraocul Implant Soc 1984; 10: 35-39.

3. Channell MM, Beckman H. Intraocular pressure changes after neodymium-YAG laser posterior capsulotomy. Arch Ophthalmol 1984; 102: 1024-1026.

4. Ficker LA, Steele AD. Complications of Nd:YAG laser posterior capsulotomy. Trans Ophthalmol Soc U K 1985; 104: 529-532.

5. Geerling G, Roider J, Schmidt-Erfurt U, et al. Initial clinical experience with the picosecond Nd:YLF laser for intraocular therapeutic applications. Br J Ophthalmol 1998; 82: 504-509.

6. Kraff MC, Sanders DR, Lieberman HL. Intraocular pressure and the corneal endothelium after neodymium-YAG laser posterior capsulotomy. Relative effects of aphakia and pseudophakia. Arch Ophthalmol 1985; 103: 511-514.

7. Slomovic AR, Parrish RK, 2nd, Forster RK, Cubillas A. Neodymium:YAG laser posterior capsulotomy. Central corneal endothelial cell density. Arch Ophthalmol 1986; 104: 536-538.


Figure 1: PPS technology versus conventional laser technology

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.